ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This review aims at exploring nanoparticle-based phototherapies of uveal melanoma (UM), the most common primary intraocular malignancy in adults with an estimated incidence of 5-7 cases per million individuals per year, a disproportionately high metastatic risk and poor prognosis in advanced stages. UM exhibits unique biological and anatomical features, including an immune-privileged ocular microenvironment, the blood-ocular barrier, and high melanin content, contributing to therapeutic complexity. Current treatments, including radiotherapy, surgery, and systemic therapies, achieve local tumor control but remain limited by adverse effects, recurrence, and insufficient efficacy against metastatic disease. Laser-based therapies, including transpupillary thermotherapy and photodynamic therapy, offer minimally invasive alternatives. However, their performance is constrained by limited light penetration, melanin-induced uneven absorption, and incomplete tumor eradication. Recent advances in nanotechnology offer opportunities to overcome these limitations. Nanoparticle-based phototherapies can improve tumor targeting, photosensitizer delivery, and localized activation while reducing off-target effects. Multifunctional nanoplatforms may combine imaging, drug delivery, and synergistic therapies such as immunotherapy or chemotherapy. Although promising preclinical results highlight improved tumor control and antitumor responses, challenges related to safety, biodistribution, and clinical translation remain. This review discusses these challenges and future directions for optimized nanoplatforms to improve disease management and metastasis prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.